ICS-FORTH’s Post

Suffolk West Director of Preconstruction Kristopher Kyle recently spoke at Bisnow's Bay Area Life Sciences Conference on a panel about building the future of lab spaces. During the panel, Kris discussed how our Gilead Sciences project in Foster City, California, is delivering flexible, sustainable, and advanced lab spaces that will help the company develop treatments in cancer and inflammatory diseases. The 182,000-square-foot building, which topped out in March, is scheduled to open next year. Thanks to Kris for representing Suffolk at this important conference, and to the other panelists for their valuable perspectives on the Bay Area life sciences industry. Photo: Elewa Camera

Only a small portion of biomedical research is put into practice. At the Center for Methods in Implementation and Prevention Science at Yale School of Public Health, we’re working to change that. 📽️ In this video, I share how our team partnered with colleagues in Nepal to expand access to cervical cancer prevention—a leading cause of cancer deaths among women, yet largely preventable. 👉 Watch the video to see how CMIPS is turning research into action: [https://lnkd.in/dW7Ajmh4] 👏 We also celebrate Dr. Archana Shrestha’s promotion to Full Professor at Kathmandu University School of Medical Sciences for her leadership in advancing global health and implementation science. 👉 Check out the full article here [https://lnkd.in/dDPYpA6R]

🇨🇭The pioneering Swiss Personalized Health Network (SPHN) enables medical innovations in fields from paediatrics to cancer, by making high-quality patient data discoverable and securely available to researchers in Switzerland. SPHN is coordinated by the Swiss Academy of Medical Sciences and SIB. Discover its successes and future direction in the #SIBProfile2025: https://lnkd.in/exdjNYcJ Davide Chiarugi, Thomas Geiger, Swiss Federal Office of Public Health FOPH #ResearchInfrastructure #PersonalizedHealth #Switzerland

Jonathan Coutinho, Professor in Neurolgy of the Amsterdam University Medical center (AUMC) on how GEMINI can impact treatment. Every six months, the GEMINI consortium unites to advance our shared goal: building a digital twin for stroke patients. The 4th Consortium Meeting in Krakow showcased how interdisciplinary alignment is accelerating progress toward personalized stroke care through digital twins. Sano and Cyfronet AGH generously hosted and facilitated the event (thank you!) and created an "aftermovie" that can be found on our website (https://dth-gemini.eu/ ). The interviews will be also posted via LinkedIn. This is the second in a series. GEMINI (A Generation of Multi-scale Digital Twins of Ischaemic and Haemorrhagic Stroke Patients) is funded by the European Union’s Horizon Europe research and innovation programme, grant number 101136438.

𝐍𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐖𝐞𝐞𝐤   This week marks National Science Week 2025, Australia’s annual celebration of science and technology. It's a time to recognise the remarkable impact of scientific discovery and the dedication of researchers who work tirelessly to improve our lives.   At Chris O’Brien Lifehouse, we’re proud to acknowledge the scientists whose expertise and commitment are driving progress in the understanding and treatment of cancer.   A key example of this innovation is the Arto Hardy Family Biomedical Innovation Hub, where multidisciplinary teams, led by Professor Jeremy Micah Crook, are pioneering new approaches to cancer care. By bringing together medical science, biology and engineering, the Hub fosters collaboration between researchers and clinicians to translate scientific breakthroughs into better outcomes for patients.   During National Science Week, we’re excited to shine a light on the important work happening within the Arto Hardy Family Biomedical Innovation Hub and to inspire continued curiosity and passion for scientific discovery. Chris O'Brien Lifehouse Research Institute Eva Tomaskovic-Crook Madison Ainsworth Renee Buggie #COBL #NationalScienceWeek #Science #Innovation #ChrisOBrienLifehouse 

⌛ Last week in Turku, Finland, the EURAS consortium held its annual in-person meeting, convening researchers, clinicians, and patient organizations from across Europe to advance the study of RASopathies — including CFC, Costello, Noonan, and SYNGAP1 syndromes. Our iBB team — PhD students Mariana Martins and Joana Jeremias, together with Professors Maria Margarida Diogo, Simão Rocha, and Tiago Fernandes — actively contributed by presenting the latest research developments and engaging with international experts. 🔬🌍 Hosted by the University of Turku, the meeting brought together 14 partners from 8 countries, fostering collaboration among research institutions, clinical teams, project coordinators, and patient advocacy groups. 🤝🧬 We are proud to represent iBB-Institute for Bioengineering and Biosciences in this consortium working to accelerate research and improve therapeutic approaches for neurodevelopmental disorders. 💙

📢 SYNTHIA is presenting at VISION Europe 2030 We are proud to share that SYNTHIA partner, the European Alliance for Personalised Medicine (EAPM), is co-organising the VISION Europe 2030 conference, taking place 2 – 3 September 2025 in Brussels. Co-funded by the EU4Health Programme, this high-level conference brings together policymakers, clinicians, researchers, patients, and industry leaders to shape the future of personalised care. Under the theme “Disruptive Technologies, Democratized Trials & Next-Gen Treatment Paradigms,” the event will explore how scientific innovation can be translated into real-world impact. 🎤SYNTHIA partner Katja Herzog, Scientific Project Coordinator at Fraunhofer ITMP, will speak in the session: “Precision Frontiers in Chronic Disease: A Global Strategy for Cancer Risk, Trials, and Treatment.” The agenda covers key topics like: AI diagnostics, Liquid biopsies, Decentralized clinical trials, Genomic equity and Public–private innovation models. #SYNTHIA #EAPM #VISIONEurope2030 #EU4Health #PersonalisedMedicine #HealthInnovation #CancerResearch #ResponsibleAI #HorizonEU

Exploring innovation in cardiogenic shock at #TexasCIC🫀 Last week, our Chief Scientific Officer, Karine Bourgeois, PhD, attended the Texas Cardiovascular Innovations Conference — a key forum for advancing critical care through emerging technologies, therapies, and best practices. A highlight of the meeting was the dedicated Cardiogenic Shock session, chaired by Dr. Nandish Thukral and Dr. Jeffrey DellaVolpe, where Dr. Adrien PICOD presented on “Mechanisms of Cardiogenic Shock and Therapeutic Targets,” including the role of DPP3 and Procizumab. We are grateful to Dr. Jeffrey DellaVolpe, Dr. Linda Sousse, and the Texas CIC team for the invitation and the collaborative spirit that drives progress in this challenging field. We are commitment to contributing to the dialogue on innovative approaches in cardiogenic shock — and we look forward to continuing the conversation in San Antonio next year.

🎥 Don’t miss this compelling interview with Dr. Ángel R. Nebreda, ICREA Professor and Group Leader of the Signalling and Cell Cycle Laboratory at IRB Barcelona—a globally recognized leader in cancer research👇 🔬 Gain insights into how his team investigates cellular signal transduction—uncovering how cells decode external cues to control critical processes like growth, differentiation, and survival, especially in the context of tumours. 🔍 Explore the pivotal role of the stress-activated p38 MAPK pathway, a central focus of Dr. Nebreda’s work, in maintaining cellular homeostasis and influencing cancer initiation and progression. 🧬 Through years of groundbreaking research, Dr. Nebreda has revealed how p38 MAPKs act as integrators of stress signals, shaping the fate of cancer cells and offering new therapeutic possibilities. 👉 Watch the full interview here ▶ https://lnkd.in/etcQ4H88 Institució Catalana de Recerca i Estudis Avançats, ICREA ICERCA - Centres de Recerca de Catalunya Barcelona Institute of Science and Technology (BIST) SOMM Alliance Parc Científic de Barcelona #CancerResearch #CellSignalling #MAPK #IRBBarcelona #IRBScience #MeetOurScientists #Oncology #Research

🚨 Spoiler Alert 🚨 Thrilled to share some exciting news: our work : “Profile of Patients with Axial Spondyloarthritis in Latin America: First Report from the ESPALDA-PANLAR Registry” has just been accepted for publication in Rheumatology International. This is the first report from the ESPALDA registry that we lead together with Fernando Sommerfleck and Wilson Bautista-Molano MD, PhD, bringing together data on #axSpA patients across Latin America, and providing a unique perspective on clinical features, regional differences, and the challenges of diagnosis and management in our region 🌎. A key step to highlight LATAM in the global research landscape and move forward in understanding axial spondyloarthritis. Thanks to the support of Panlar and all the Latin American researchers who participated in this project. 👉 Stay tuned for more details on the findings and their impact.